Opinion: A ‘great listening’ to patients could be a powerful legacy of the pandemic
A lasting memorial may be emerging for the millions of people who will have tragically…
Category: Pharmaceuticals
‘Stuck in a cul-de-sac’: Researchers are finally breaking away from the central dogma of depression
Geoffrey Attardo first tried Prozac to treat his depression when he was doing postdoctoral research…
STAT+: STAT+ Conversation: Blueprint for cancer drugs
Editor’s note: A livestream of the conversation will be embedded below at 1 p.m. ET….
STAT+: U.K. antitrust watchdog issues a provisional ruling that Pfizer engaged in price gouging
After being forced to reassess its original findings, a U.K. antitrust watchdog has issued a…
STAT+: Bayer inks a $1.5 billion deal for a biotech with a proprietary drug discovery platform
In a bid to quickly broaden its drug discovery abilities, Bayer (BAYRY) has reached a…
STAT+: Canadian agency loses a battle in effort to force a drug maker to lower ‘excessive’ pricing
In a withering ruling, a Canadian appeals court overturned a controversial decision issued four years…
Alzheimer’s patients are in limbo as hospitals, insurers grapple with whether to offer Aduhelm
For all the explosive controversy over the approval of the first treatment for Alzheimer’s disease…
STAT+: FDA to importer: keep your active pharma ingredients away from weed killer and antifreeze
What do weed killer, engine antifreeze coolant, dry wall repair products, and active pharmaceutical ingredients…
Opinion: STAT+: Stifling biopharma mergers would kill the innovation economy that generates new therapies
The headlines speak of a biotech boom with news of company launches, oversubscribed private financings,…
STAT+: FDA threatens to fine another drug maker for failing to report clinical trial results
For only the second time, the Food and Drug Administration is threatening to fine a…
Opinion: The FDA just broke the logjam on interchangeable biologics. Here’s what that decision means
The Food and Drug Administration’s decision on Wednesday to approve a long-acting insulin called Semglee…
STAT+: FDA approves the first interchangeable biosimilar insulin. Will it really lower the cost?
In a long-awaited move, the Food and Drug Administration has approved the first so-called interchangeable…
STAT+: Hospitals and pharma are both on the hook to help fund infrastructure deal
WASHINGTON — Both hospitals and drug makers are on the hook to help pay for…
.jpg)
STAT+: Animal rights activists get new ammunition in their battle over a controversial rodent test
In what animal rights activists see as a significant development, a pair of U.K. health…
Opinion: On compounding, the FDA marches to the beat of its own biases
The FDA’s approval of the drug Aduhelm as a treatment for Alzheimer’s disease — despite…
Biden wants to bolster the pharma supply chain. A major generic plant closing may make that harder
If you think bolstering the pharmaceutical supply chain in the U.S. is a national priority,…
STAT+: Pharmalittle: A race to develop Covid-19 pills is underway; Russian trolls target Pfizer vaccine
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Biogen’s ‘symptom quiz’ for Aduhelm draws fire; most U.S. clinical trials flunk transparency rules
Good morning. Elizabeth Cooney sitting in for Ed Silverman on what from here looks like…
STAT+: Most clinical trials failed to meet U.S. transparency requirements for recently approved drugs
In the latest look at clinical trial transparency, a new analysis found that only 26%…
States reach $26 billion deal with three wholesalers and J&J to end opioid lawsuits
Three of the largest pharmaceutical wholesalers and a major drug maker reached a $26 billion…
STAT+: Pharmalittle: Pfizer cuts deal for Covid-19 shot to be partially made in South Africa; wholesalers to pay $1.1b to NY to settle opioid suit
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: FDA plans to study whether pharma reps at conference exhibit booths are telling the truth
Pandemics aside, medical conferences are popular destinations for doctors, who are barraged with information about…
STAT+: As a key hearing nears, Justice Department calls Purdue’s bankruptcy plan unconstitutional
In harsh words, the U.S. Department of Justice castigated Purdue Pharma’s proposed bankruptcy plan as…
STAT+: STAT+ Conversations: the revitalization of the antibiotic drug pipeline
Editor’s note: A livestream of the conversation will be embedded below at 1 p.m. ET….
STAT+: Pharma CEOs, lobbyists showered Democrat with cash after his attempt to torpedo Pelosi’s drug pricing bill
WASHINGTON — The very next day after Rep. Scott Peters attempted to torpedo House Speaker…
STAT+: Dutch authorities fine drug maker $23 million for ‘excessive’ pricing of a rare disease drug
Antitrust regulators in the Netherlands have fined a drug maker $23 million for years of…
STAT+: Expert panel votes unanimously that Biogen Alzheimer’s drug doesn’t offer patient benefits
A prominent panel of medical experts unanimously voted that there is no evidence to suggest…
STAT+: U.K. issues record fine to drug makers for price gouging and collusion schemes
After a lengthy investigation, the U.K. antitrust regulator has fined several drug makers a record-setting…
Opinion: With Aduhelm, is history repeating itself with another win for Wall Street and a loss for patients?
When I learned of the Food and Drug Administration’s approval of aducanumab (Aduhelm) for Alzheimer’s…
STAT+: House Democrats say pharma stock buybacks and dividends exceed R&D spending
A Congressional committee released a report on Thursday showing the 14 largest drug makers spent…
STAT+: Purdue wants to shower employees with nearly $35 million in different kinds of bonuses
As Purdue Pharma attempts to win a controversial reorganization plan in bankruptcy court, the drug…
Johnson & Johnson agrees to pay $230 million to settle opioid case in New York
On the eve of a widely anticipated trial, Johnson & Johnson (JNJ) has agreed to…
STAT+: Pharma has a ‘hidden’ influence over U.K. Parliament members through funding, analysis shows
The pharmaceutical industry has developed a “hidden web of policy influence” over members of the…
STAT+: Pfizer halts global distribution of smoking cessation pill as it tests for potential carcinogens
After finding potential carcinogens in some lots of Chantix, Pfizer (PFE) late last month halted…
.jpg)
STAT+: Pharmalittle: Lilly seeks speedy U.S. approval for its Alzheimer’s drug; FDA’s Woodcock ‘not concerned’ about criticism
Hello, everyone, and nice to see you again after a day off. We can explain…
STAT+: In reversal, Eli Lilly now intends to seek fast approval for Alzheimer’s treatment
Eli Lilly said Thursday that it will seek a fast U.S. approval for its drug…
STAT+: FDA’s Woodcock is just ‘not that concerned’ about the criticism over Biogen’s Alzheimer’s drug, Aduhelm
WASHINGTON — The Food and Drug Administration has been without a permanent commissioner for six…
STAT+: Key science officials detail their plans for a new research agency — and Congress is getting closer to funding it
WASHINGTON — Two key federal health officials are pitching a new branch of the National…
STAT+: Pharmalittle: Biogen isn’t the only company to make big bucks from its Alzheimer’s drug; EU extends Covid-19 vax export block
Hello, everyone, and how are you this morning? Some puffy clouds are hovering over the…
STAT+: Billions spent on prescription drug ads may have increased Medicare spending
The large sums of money spent on advertising prescription drugs directly to consumers may have…
Listen: The Covid vaccine booster debate, 23andMe hits Wall Street, & biotech’s call of the decade
Is 23andMe a tech company? Do we really need booster shots of Covid-19 vaccines? And…
Opinion: Why a controversial decision won’t stop me from serving on FDA advisory committees
Last week’s controversial decision by the FDA to give aducanumab, Biogen’s Alzheimer’s drug, accelerated approval…
Opinion: Listen: Two Alzheimer’s experts with opposing viewpoints on Aduhelm
This week’s “First Opinion Podcast” is a special two-part episode focusing on the controversial —…
STAT+: Buying the data: Health care lobbyists fund their own policy analyses, clouding Washington debates
WASHINGTON — Sen. Chuck Grassley’s voice boomed through the Senate hearing room — it sounded…
STAT+: GSK pays up big for rights to TIGIT-targeted cancer immunotherapy from Iteos
Iteos Therapeutics said Monday that it has sold ownership rights to an experimental anti-TIGIT cancer…
STAT+: ‘Simply unacceptable’: Alzheimer’s Association blasts Biogen over the price of its new medicine
In harsh tones, the Alzheimer’s Association sharply criticized Biogen (BIIB) for the $56,000 price tag…
Listen: Every angle on the FDA’s polarizing approval of Biogen’s Alzheimer’s drug
Was the FDA right to approve Aduhelm? What’s a fair price for a debatable drug?…
STAT+: Radioactive drug helps men with advanced prostate cancer, but survival benefit is debated
A Novartis drug that delivers a lethal dose of radiation directly to prostate cancer cells…
STAT+: Martin Shkreli’s longtime friend wants to undo his 4,000% price hike. But first he’ll have to finally oust the ‘pharma bro’
Martin Shkreli’s drug company has a lot of problems. Revenue was cut in half last…
STAT+: For first time, immunotherapy after surgery shows benefit for patients with early kidney cancer
Merck said Thursday that giving its drug Keytruda immediately after surgery significantly reduced the risk…